December 17, 2021 -- 20n Bio (20n), an artificial intelligence (AI)-powered drug discovery company focused on designing new proteins for therapeutics, has raised a $3.3 million in seed funding. 20n said it will use the proceeds to expand its scientific team, establish a discovery platform, and start multiple early studies in oncology and other genetic diseases.
Mingfu Zhu, PhD, founded the company in September 2021. Zhu has co-founded several AI-powered biotech companies in drug discovery and cancer diagnostics previously.
20n plans to quickly scale its current team of five full-time PhD-level employees and hire more scientists in computational protein design and RNA biology, the company said. Recently, 20n added two computational structural biologists to its scientific advisory board: Yaoqi Zhou, PhD, and Longxing Cao, PhD, who is a finalist of MIT's Technology Review Innovators Under 35 Asia Pacific 2021.
The funding was led by BlueRun Ventures China.